|
| Press Releases |
|
 |
|
| Monday, December 15, 2025 |
|
|
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China |
| more info >> |
|
| Thursday, December 11, 2025 |
|
|
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China |
| China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) ("Y-3 for Injection" or the "Product") has been accepted by National Medical Products Administration of the People's Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. more info >> |
|
| Thursday, October 30, 2025 |
|
|
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China |
| China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiary, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection ("MG-K10" or the "Product"). more info >> |
|
| Monday, October 27, 2025 |
|
|
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R) |
| more info >> |
|
| Sunday, September 28, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication |
| China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiaries, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the "Trial") of ruxolitinib cream (the "Product") in patients with mild to moderate atopic dermatitis (AD) in China. more info >> |
|
| Tuesday, September 23, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the "Agreements") with Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, "Vecantoxatug") indicated for passive immunization against tetanus and Silevimig Injection (GR1801, "Silevimig") indicated for passive immunization following suspected rabies virus exposure, respectively. more info >> |
|
| Tuesday, August 19, 2025 |
|
|
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers |
| On 18 August, China Medical System Holdings Limited ("CMS" or the "Company") announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. more info >> |
|
| Tuesday, July 29, 2025 |
|
|
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) ("ZUNVEYL" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
| Tuesday, July 22, 2025 |
|
|
CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets |
| On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited ("CMS" or the "Group") on the Main Board of the Singapore Exchange ("SGX"), SGX and CMS co-hosted the "Singapore and Emerging Markets Pharmaceutical Industry Growth Forum & CMS SGX Secondary Listing Appreciation Dinner". more info >> |
|
| Monday, April 1, 2024 |
|
|
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia |
| more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis
Mar 12, 2026 13:50 JST
|
|
|
Yuexiu REIT Maintains Operational Resilience, Revenue Exceeds RMB1.8 Billion in 2025
Mar 12, 2026 12:42 HKT/SGT
|
|
|
Axonex Intelligence and Synergy Technology Group Form Joint Venture to Accelerate Digital Twin and Drone Flight Control Expansion
Mar 12, 2026 11:43 HKT/SGT
|
|
|
NEC and The University of Tokyo calculate carbon accumulation rates in Malaysian national park with a 9.4% margin of error
Mar 12, 2026 12:02 JST
|
|
|
More than 1,000 top buyers to attend! Procurement opportunities at China Chaoshan International Textile and Garment Exhibition
Mar 12, 2026 11:00 HKT/SGT
|
|
|
Japantastics Introduces the World of Kodaimoji, Bringing Ancient Characters into Modern Spaces 
Mar 12, 2026 11:00 JST
|
|
|
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference
Mar 12, 2026 00:00 HKT/SGT
|
|
|
MarketingPulse and eTailingPulse open next Thursday
Mar 11, 2026 16:54 HKT/SGT
|
|
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Mar 11, 2026 12:07 JST
|
|
|
JOYY Reports 4Q and FY2025 Financial Results: Q4 Revenue Returns to YoY Growth, BIGO Ads Up 61.5% YoY
Mar 11, 2026 09:40 HKT/SGT
|
|
|
Kincora Consolidates, Commences Geophysics and Forms Partnership at Cowal East
Mar 10, 2026 17:59 HKT/SGT
|
|
|
Fosun Navigates Cyclical Volatility and Clears Risks as Management Reaffirms RMB10 Bn Profit Target for Next 3 to 5 Yrs
Mar 10, 2026 15:45 HKT/SGT
|
|
|
Impro Precision 2025 Profit Attributable to Shareholders Reaches Record High of HK$726.2 Million, Up 12.7% Year-on-Year, Forecast 2026 Sales Growth Rate to Accelerate to Mid-Double Digits
Mar 10, 2026 14:19 HKT/SGT
|
|
|
Natural Beauty's 2025 Annual Results Show Steady & Robust Growth
Mar 10, 2026 13:35 HKT/SGT
|
|
|
Xiamen C&D Inc.'s New Five-Year Strategic Plan Released, Aiming to Accelerate Globalization
Mar 10, 2026 12:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
